Testing for KRAS has already been performed in metastatic CRC to determine eligibility for anti-EGFR monoclonal antibody therapies, such as cetuximab or panitumumab, making it a readily usable predictive marker. This evidence concerns the gene EGFR and colorectal carcinoma.